The US Food and Drug Administration's proposed budget for its nine-year campus consolidation project has now been brought down to $810 million from a level of $890 million at the start of the year (Marketletter January 9), and massively below the first estimates of $1.4 billion announced in 1990.
FDA Commissioner David Kessler told a House hearing that the reductions had been achieved by the agency and the General Services Administration going "back and back again to ensure that the project is the most efficient it can be and to cut things that we don't need." He also assured the hearing that the current project, as outlined, "will meet FDA's needs well into the 21st century."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze